ERBB2 and triple-negative breast carcinoma: When the cohort was stratified into Luminal A, Luminal B HER2-, Luminal B HER2+, HER2-enriched (non-luminal), and triple-negative breast cancer (TNBC), stage distribution differed significantly (χ2 (5) = 14.08, p = 0.015).